Abstracts tagged "Access to care"

Abstract Number: 1164 • 2014 ACR/ARHP Annual Meeting
Inequity: Level of Education Is Associated with Access to Biologic Dmards Even in a Country with Highly Developed Social Welfare (Norway)
Polina Putrik¹, Sofia Ramiro², Elisabeth Lie³, Andras Keszei⁴, Desirée van der Heijde⁵, Robert Landewé⁶, Tore K. Kvien⁷, Till Uhlig⁷ and Annelies Boonen⁸, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁷Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose Biologic DMARDs (bDMARDs) have greatly improved the outcome of rheumatoid arthritis (RA). Investigating possible inequities in access to bDMARDs across socio-economic factors is important,…
Abstract Number: 1153 • 2014 ACR/ARHP Annual Meeting
Area of Residence and Socio-Economic Factors Significantly Affect Access to Biological Therapy for Rheumatoid Arthritis Patients in Romania
Catalin Codreanu¹, Corina Mogosan², Ruxandra Ionescu³, Ioan Ancuta⁴, Magda Parvu⁵ and Simona Rednic⁶, ¹5 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ²'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ³Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ⁴“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ⁵Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, ⁶Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania
Background/Purpose Clinical trials have proven the efficacy of biological therapy for rheumatoid arthritis (RA) worldwide. However, high costs have set boundaries to their use, especially…
Abstract Number: 901 • 2014 ACR/ARHP Annual Meeting
Rate of Serum Uric Acid (SUA) Assessment in Gout Patients Treated with Urate-Lowering Therapy: Treating to Target?
Robert Morlock¹, David M. Kern², Ozgur Tunceli², Siting Zhou², Laura Horne³, Sulabha Ramachandran³ and Hyon K. Choi⁴, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²HealthCore, Inc., Wilmington, DE, ³AstraZeneca, Wilmington, DE, ⁴Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by chronic hyperuricemia, leading to urate crystal deposition disease and subsequent intermittent…
Abstract Number: 94 • 2014 ACR/ARHP Annual Meeting
Possible Effects of Medicare-Only Insurance Coverage on the Use of Biologics in Patients with RA
Marcia Genta, Dallas Arthritis Center, Dallas, TX
Background/Purpose: Biologics, a relatively new widely used class of medication that can substantially improve the course of RA, are expensive and their use is not…
Abstract Number: 1760 • 2013 ACR/ARHP Annual Meeting
Relationships Between Driving Distance, Rheumatoid Arthritis Diagnosis, and Disease-Modifying Anti-Rheumatic Drug Receipt
Jennifer M. Polinski¹, M. Alan Brookhart², John Z. Ayanian³, Jeffrey N. Katz⁴, Seo Young Kim⁵, Chris Tonner⁶, Edward H. Yelin⁷ and Daniel H. Solomon^8,9, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ²University of North Carolina, Chapel Hill, NC, ³Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology; Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁶Medicine, University of California, San Francisco, San Francisco, CA, ⁷Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁸Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁹Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are recommended for all patients with rheumatoid arthritis (RA). Some studies estimate that almost half of patients with RA do…
Abstract Number: 2908 • 2013 ACR/ARHP Annual Meeting
The Roles Of Nurse Practitioners and Physician Assistants In Rheumatology Practices In The United States
Erika Brown¹, Asaf Bitton², Liana Fraenkel³, Hsun Tsao⁴, Jeffrey N. Katz⁵ and Daniel H. Solomon^1,6, ¹Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Medicine, Brigham and Women's Hospital, Boston, MA, ³Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: A recent workforce study of rheumatology in the US suggests that during the next several decades the demand for rheumatology services will outstrip the…
Abstract Number: 2511 • 2012 ACR/ARHP Annual Meeting
Potential Barriers That Limit Access to Rheumatologists Among Patients with Early Rheumatoid Arthritis in a Universal Access Health Care System
Jessica Widdifield¹, J. Michael Paterson², Sasha Bernatsky³, Karen Tu², Nadia Gunraj², Noah Ivers¹, Debra Butt², R. Liisa Jaakkimainen⁴, J. Carter Thorne⁵, Vandana Ahluwalia⁶ and Claire Bombardier⁷, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ⁴Preventive Med and Biostatisti, University of Toronto, Toronto, ON, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶William Osler Health Center, Brampton, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Current guidelines for the optimal care of rheumatoid arthritis (RA) recommend prompt referral to a rheumatologist. In the province of Ontario, Canada all 13…
Abstract Number: 2041 • 2012 ACR/ARHP Annual Meeting
Improving Access and Patient Education in Rheumatology: the Gout Shared Medical Appointment; a Quality Improvement Initiative
Alicia J. Zbehlik¹ and Nicole M. Orzechowski², ¹Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Section of Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH
Background/Purpose: Patients experience long waits for consultations in Rheumatology at Dartmouth-Hitchcock Medical Center (DHMC). The cause of this is multi-factorial, including provider referral patterns, patient preferences,…
Abstract Number: 2012 • 2012 ACR/ARHP Annual Meeting
Pediatric Rheumatology Productivity: Results of the American Academy of Pediatrics 2010 Workforce Survey
Michael Henrickson¹ and Laura Laskosz², ¹MLC 4010, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Technical and Medical Services, The American Academy of Pediatrics, Elk Grove Village, IL
Background/Purpose: Relative value units (RVUs) are a payer-neutral measure of clinical work. The federal government uses a multi-component formula to convert this measure into reimbursement.…
Abstract Number: 1844 • 2012 ACR/ARHP Annual Meeting
Inequities in Access to Biologic Disease-Modifying Anti-Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries
Polina Putrik¹, Sofia Ramiro², Milena Pavlova³, Tore K. Kvien⁴, Tuulikki Sokka⁵, Till Uhlig⁴, Annelies Boonen⁶ and Equity In Access To Treatment of RA Across Europe⁷, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ³Health Services Research, Maastricht University, Maastricht, Netherlands, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁷European Region
Background/Purpose: In the treatment of patients with RA, EULAR recommends to initiate biologic DMARDs after failing synthetic DMARDs. However, biologics are costly, and it is…
Abstract Number: 1721 • 2012 ACR/ARHP Annual Meeting
Development of User-Focused Standards of Care for Rheumatoid Arthritis the Www.Eumusc.Net Project – Work Package 5
Michaela Stoffer¹, Josef S. Smolen², Anthony D. Woolf³, Tanja A. Stamm⁴ and EUMUSC.net working group WP 5⁵, ¹Internal Medicine III, division of rheumatology, Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ³Rheumatology Dept, Royal Cornwall Hospital, Truro Cornwall, United Kingdom, ⁴Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Royal Cornwall Hospital Treliske, Truro Cornwall, United Kingdom
Background/Purpose: The EUMUSC.net project facilitates cooperation between EU Member States and promotes a comprehensive European strategy to optimise musculoskeletal health.The purpose of Work package 5,…
Abstract Number: 925 • 2012 ACR/ARHP Annual Meeting
Use of Rheumatology Services for Arthritis: The Role of SES and Geographic Availability of Rheumatologists and Primary Care Physicians
E. M. Badley¹, Mayilee Canizares² and Aileen M. Davis³, ¹Division of Health Care and Outcomes Research,Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Division of Health Care and Outcomes Research,Toronto Western Research Institute, Toronto, ON, Toronto, ON, Canada, ³Division of Health Care and Outcomes Research, Toronto Western Research Institute, Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Access to rheumatology is critical for timely treatment of new onset inflammatory arthritis (IA). Barriers to timely care include patient characteristics, the need for…
Abstract Number: 287 • 2012 ACR/ARHP Annual Meeting
Variation in Healthcare Utilization by Region and Number of Rheumatologists Per State Among Pediatric Medicaid Patients with Lupus Nephritis Prior to End-Stage Renal Disease in the United States, 2000-2004
Linda T. Hiraki¹, Candace H. Feldman², Graciela S. Alarcon³, Jun Liu⁴, Michael A. Fischer⁵, Wolfgang C. Winkelmayer⁶ and Karen H. Costenbader⁷, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁷Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Unequal healthcare access and utilization may contribute to the striking sociodemographic disparities seen in outcomes for children with lupus nephritis. Medicaid is the U.S.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].